Interview: Evgeniy Gaydukov – Country Director, AstraZeneca Ukraine
Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the…
AstraZeneca UK
Last updated: 07.09.2018
Address: London, England W1K 1LN,United Kingdom
Tel: 0207 604 8032
Web: http://www.astrazeneca.co.uk/home/
Company description
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland, USA (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.[6]
The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group[7][8] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.
Products and services
Cardivascular medicine
Gastrointestinal medicines
Infection medicines
Oncology medicines
Neuroscience medicines
Respiratory and Inflammation medicines
Interviews
Interview with Mark Jones, Marketing Company President, AstraZeneca UK
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market…
Related
UK / Fastest Growing Private Pharmacos; GSK Shake-Up; Brexit Uncertainties; COVID-19 Reinfection Trial
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma…
M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
MEA / Pfizer’s Saudi Transformation; Urgent Call for Arab Import Reform; Hikma & Tabuk Deals
The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi…
Europe / After Brexit: Focus on the New Pharmaceutical Strategy for Europe
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the…
Saudi Arabia / 5 Pharma Companies to Know
Following on from our list of the overall top 10 companies in the Saudi Arabian pharma market, here PharmaBoardroom…
Japan / Taiho Pharmaceutical: An Oral Chemotherapy Pioneer
Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known…
UK / New Post-Brexit Regulatory Alliance with Australia, Canada, Singapore & Switzerland
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
UK-Japan FTA / Banishing UK Pharma's Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
Rankings / Top 10 Pharma Companies in Saudi Arabia
The top 10 pharma companies in Saudi Arabia ranked by sales value in USD millions MAT Q1 2019. These top 10…
UK / MSD to Build USD 1.3 Billion London Research Hub in Boon for Post-Brexit Britain
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Opinion / 3 Ways the UK’s Pharma Sector is Driving Innovation
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Top 10 / Pharma Companies in Japan
Japan’s pharma market is one of the world’s biggest, with a value of around USD 95 billion, according…
